JESUS MARIA
FERNANDEZ GOMEZ
Profesor Titular de Universidad
Hospital Universitario de Basurto
Bilbao, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Basurto (14)
2020
-
Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry
Actas Urologicas Espanolas, Vol. 44, Núm. 3, pp. 156-163
2018
-
Actualización del papel de la quimioterapia endovesical en el cáncer de vejiga no músculo-invasivo
Actas Urologicas Espanolas
-
Review of evidence on handling hazardous drugs and Products in Urology Services; Consensus document between the Spanish Urology Association and the Spanish Society of Health-System Pharmacists
Biomedical Instrumentation and Technology, Vol. 42, Núm. 5, pp. 212-215
-
Review of the evidence on handling drugs and hazardous products in Urology Departments. Consensus document between the Spanish Urological Association and the Spanish Society of Hospital Pharmacy
Actas Urologicas Espanolas, Vol. 42, Núm. 6, pp. 375-380
-
Revisión de la evidencia sobre el manejo de medicamentos y productos peligrosos en los servicios de Urología; documento de consenso entre la Asociación Española de Urología y la Sociedad Española de Farmacia Hospitalaria
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 42, Núm. 5, pp. 212-215
2017
-
Diagnosis and treatment for clinically localized prostate cancer. Adherence to the European Association of Urology clinical guidelines in a nationwide population-based study – GESCAP group
Actas Urologicas Espanolas, Vol. 41, Núm. 6, pp. 359-367
2016
-
Tendencias de tratamiento en el cáncer de próstata clínicamente localizado. Análisis poblacional a nivel nacional: grupo GESCAP
Actas Urologicas Espanolas, Vol. 40, Núm. 4, pp. 209-216
2015
-
Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013
European Urology, Vol. 68, Núm. 2, pp. 256-262
-
Sequential combination of mitomycin C plus bacillus calmette-guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: Final outcome of CUETO 93009, a randomized prospective trial
European Urology, Vol. 67, Núm. 3, pp. 508-516
2011
2009
-
Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model
Journal of Urology, Vol. 182, Núm. 5, pp. 2195-2203
2008
-
Prognostic Factors in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials
European Urology, Vol. 53, Núm. 5, pp. 992-1002
2007
-
A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C
European Urology, Vol. 52, Núm. 5, pp. 1398-1406
2005
-
Has a 3-fold decreased dose of Bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial
Journal of Urology, Vol. 174, Núm. 4 I, pp. 1242-1247